Pharmacogenomics, Год журнала: 2025, Номер unknown, С. 1 - 13

Опубликована: Апрель 11, 2025

As an emerging health technology, pharmacogenetic (PGx) testing has the capacity to improve medication therapy. However, implementation in medically underserved populations (MUPs) remains limited, which potential increase healthcare disparities. While there is no single accepted definition for MUPs, demographic, socioeconomic, cultural, and geographic factors can lead reduced access healthcare, contributes disparate outcomes these populations. In case of PGx testing, as MUPs have increased risk adverse drug events, lower numbers encounters, are prescribed more medications be guided by additional benefits from may occur MUPs. Study acceptability perceptions reported literature, provides support development successful implementations. Additionally, a few limited pilot implementations assessed feasibility. further studies establishing feasibility effectiveness will enable widespread those who underserved. Thus, this narrative review explores impact medical underservice on health, testing's research early clinical

Язык: Английский